Genome Biologics
|
Year Established:
2016 |
|
|
Website:
genomebiologics.com |
|
|
Headquarters:
Frankfurt am Main, Hessen, DE |
|
|
Company Type:
Mid-Sized Business (10-100M TTM Revenue) |
Genome Biologics is leaders in therapeutic target discovery and RNA-targeted therapies in Cardiovascular Disease.
We have developed a seamless integrated platform that directly couples the output of complex AI-driven human disease genetic analysis – GENIMAPS – to the capacity to model the disease heterogeneity– directly in ex vivo patient-derived heart tissue TrueCardium AND in small and large animals with our patented GENISYST technology.
Through application of our integrated technologies – we are Increasing the physiological accuracy and relevance of preclinical drug development and at the same time reducing discovery time and cost. As a platform output, we have developed a rich therapeutic pipeline for Heart Failure, CHIP, Cardiotoxicity and rare disease. We aim to initiate Phase 1 studies with our lead compound in 2022.
| Site | Badges | |
|---|---|---|
| Address Institute of Cardiovascular Regeneration, Centre for Molecular Medicine, Building 25B, 5th floor Frankfurt am Main, Hessen, 60590 Germany | ||
| Genome Biologics UG Institute of Cardiovascular Regeneration, Centre for Molecular Medicine, Building 25B, 5th floor Frankfurt am Main, Hessen, 60590 Germany | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.